Neutel Joel M, Elliott William J, Izzo Joseph L, Chen Chao L, Masonson Harvey N
Orange County Heart Institute and Research Center, Orange, CA 92868, USA.
J Clin Hypertens (Greenwich). 2002 Sep-Oct;4(5):325-31. doi: 10.1111/j.1524-6175.2002.01051.x.
Olmesartan medoxomil is a new angiotensin II receptor blocker. In this randomized, double-blind, placebo-controlled study, the efficacy and safety of olmesartan medoxomil was assessed in 334 patients with moderate to severe essential hypertension. Patients were randomized to receive placebo; 5, 20, or 80 mg olmesartan medoxomil q.d.; or 2.5, 10, or 40 mg olmesartan medoxomil b.i.d. Ambulatory and cuff blood pressure were measured prior to and after 8 weeks of treatment. Treatment with olmesartan medoxomil resulted in a significant placebo-adjusted reduction of mean 24-hour ambulatory diastolic blood pressure of 9.6 mm Hg, 12.2 mm Hg, and 10.6 mm Hg in the 5-, 20-, and 80-mg q.d. groups, respectively. Corresponding reductions in mean ambulatory systolic blood pressure were 14.5 mm Hg, 16.5 mm Hg, and 15.4 mm Hg. Similar reductions of diastolic and systolic blood pressure were seen with b.i.d. dosing. The diastolic trough-to-peak ratios of the q.d. doses of olmesartan medoxomil ranged from 57%-70%, indicating 24-hour effectiveness. The safety profile of olmesartan medoxomil was similar to that of placebo. Olmesartan medoxomil appears to be a safe and effective once-a-day treatment for hypertension.
奥美沙坦酯是一种新型血管紧张素II受体阻滞剂。在这项随机、双盲、安慰剂对照研究中，对334例中重度原发性高血压患者评估了奥美沙坦酯的疗效和安全性。患者被随机分为接受安慰剂；每日一次服用5、20或80毫克奥美沙坦酯；或每日两次服用2.5、10或40毫克奥美沙坦酯。在治疗8周前后测量动态血压和袖带血压。奥美沙坦酯治疗使每日一次服用5毫克、20毫克和80毫克组的平均24小时动态舒张压较安慰剂调整后分别显著降低9.6毫米汞柱、12.2毫米汞柱和10.6毫米汞柱。平均动态收缩压相应降低分别为14.5毫米汞柱、16.5毫米汞柱和15.4毫米汞柱。每日两次给药时，舒张压和收缩压也有类似降低。奥美沙坦酯每日一次剂量的舒张压谷峰比在57%-70%之间，表明有24小时疗效。奥美沙坦酯的安全性与安慰剂相似。奥美沙坦酯似乎是一种安全有效的高血压一日一次治疗药物。
